Document:

Execution Copy

                                    AMENDMENT NO. 1 dated as of March 14, 2003
                                    to the U.S. Commercialization Agreement
                                    dated as of April 26, 2002 between Genta
                                    Incorporated ("Genta") and Aventis
                                    Pharmaceuticals Inc. ("Aventis") (as the
                                    same may be amended, supplemented or
                                    otherwise modified, the "U.S.
                                    Commercialization Agreement").

                             INTRODUCTORY STATEMENT

            Reference is made to that certain U.S. Commercialization Agreement
dated as of April 26, 2002 between Genta and Aventis concerning the development
and commercialization of products containing or comprising an antisense compound
known as G3139 (also known as oblimersen sodium).

            In order to facilitate its performance of its obligations under the
U.S. Commercialization Agreement, Genta has requested and Aventis has agreed
that Aventis establish a secured revolving line of credit pursuant to which
Aventis would make advances to Genta from time to time in an aggregate principal
amount, together with all accrued and unpaid interest, not to exceed $40,000,000
at any one time outstanding.

            Accordingly, Genta and Aventis have agreed to amend the U.S.
Commercialization Agreement, all on the terms and subject to the conditions
hereinafter set forth.

            Therefore, the parties hereto hereby agree as follows:

            Section 1. Defined Terms. Capitalized terms used herein and not
otherwise defined herein shall have the meaning given them in the U.S.
Commercialization Agreement.

            Section 2. Amendments to the U.S. Commercialization Agreement.
Subject to the satisfaction of the conditions precedent set forth in Section 3
hereof, the U.S. Commercialization Agreement is hereby amended as of the
Effective Date (as hereinafter defined) as follows:

            (A) Section 1 of the U.S. Commercialization Agreement is hereby
amended by adding the following definitions in the appropriate alphabetical
sequence:

            "Accrued Amount" shall mean, as of any relevant period of time, all
accrued Development Costs owing from Aventis to Genta for the immediately
preceding three full calendar months, net of any amounts owing from Genta to
Aventis for such three month period.

            "Advance" shall have the meaning given such term in Section 19.1
hereof.

            "Advance Default" shall have the meaning given such term in Section
19.8 hereof.
<PAGE>

            "Applicable Law" shall mean all provisions of statutes, rules,
regulations and orders of the United States or foreign governmental bodies or
regulatory agencies applicable to a Person, and all orders and decrees of all
courts and arbitrators in proceedings or actions in which the Person in question
is a party.

            "Borrowing Base" shall mean, at any date for which the amount
thereof is to be determined, an amount equal to the aggregate of (i) (*) of the
Accrued Amount plus (ii) the Over Advance Amount.

            "Borrowing Base Report" shall be as defined in Section 19.1(g)
hereof.

            "Borrowing Certificate" shall be as defined in Section 19.6 hereof.

            "Borrowing Request Date" shall mean the date on which Genta delivers
to Aventis the notice required by Section 19.1(c).

            "Business Day" shall mean any day other than a Saturday, Sunday or
other day on which banks are permitted to close in the States of New York and
New Jersey.

            "Code" shall mean the Internal Revenue Code of 1986, as amended.

            "Collateral" shall have the meaning given such term in the Security
Agreement.

            "Commitment" shall mean the commitment of Aventis to make Advances
to Genta from the Closing Date through the Commitment Termination Date in a
principal amount and together with all accrued and unpaid interest thereon, in
the aggregate, at any one time outstanding not to exceed $40,000,000.

            "Commitment Termination Date" shall mean the earliest to occur of:
(i) the receipt of NDA Approval for the Product, (ii) the giving of notice by
either Genta or Aventis of the termination of this Agreement in accordance with
Section 15 hereof, (iii) the giving of notice by Genta of the termination of the
Commitment, (iv) the termination of the Commitment pursuant to Section 19.8
hereof, (v) an event shall occur which would have a material adverse effect on
the ability of Genta to perform its respective obligations hereunder or under
the Security Agreement, as determined by Aventis in its reasonable good faith
judgement, and (vi) December 31, 2004.

            "Development Cost Report" shall be as defined in Section 19.1(g)
hereof.

            "Dollars" and "$" shall mean lawful money of the United States of
America.

            "Global Supply Agreement" shall mean the Global Supply Agreement
dated as of April 26, 2002 among Genta, Aventis and Aventis Ireland Limited
(formerly Garliston Limited).

            "Governmental Authority" shall mean any federal, state, municipal or
other governmental department, commission, board, bureau, agency or
instrumentality, or any court, in each case whether of the United States or any
foreign jurisdiction.

                                      -2-
<PAGE>

            (*)

            "Maturity Date" shall mean the date that is the earlier of: (i)
acceleration of the Advances upon the occurrence of an Advance Default, or (ii)
six months after any other event that constitutes a Commitment Termination Date.

            "Maximum Advance" shall mean at any time for which it is to be
determined, the lesser of the Commitment or the Borrowing Base.

            "Over Advance Amount" shall mean an amount, determined by Aventis in
its reasonable good faith discretion from time to time but no less frequently
than once at the beginning of each Calendar Quarter, which represents the sum of
(*). Notwithstanding the foregoing, if an event occurs that is reasonably
expected to cause a material change in the Over Advance Amount as most recently
determined by Aventis, then Genta may propose and Aventis shall consider in good
faith a change to the Over Advance Amount.

            "Person" shall mean any natural person, corporation, division of a
corporation, partnership, trust, joint venture, association, company, estate,
unincorporated organization or government or any agency or political subdivision
thereof.

            (*)

            "Security Agreement" shall mean the security agreement between Genta
and Aventis dated as of the date of this Amendment No. 1 to the U.S.
Commercialization Agreement and attached hereto as Exhibit A.

            (B) Section 6.2.1 of the U.S. Commercialization Agreement is hereby
amended by (i) deleting Section 6.2.1(A) in its entirety, (ii) deleting Section
6.2.2 in its entirety and (iii) changing the number "35 million" appearing in
Section 6.2.1(B) to "75 million".

            (C) Section 6.2.3 of the U.S. Commercialization Agreement is hereby
amended by deleting the words "and the same indication may trigger the milestone
payment under Event A (*) and any other Event" appearing in the last sentence
thereof.

            (D) For purposes of clarification, the Parties agree that (*).

            (E) A new Article 19 entitled "Advances to Genta" is hereby added to
the U.S. Commercialization Agreement to read as follows:

ARTICLE 19 ADVANCES TO GENTA

            SECTION 19.1 Advances.

            (a) Aventis agrees, upon the terms and subject to the conditions
hereinafter set forth, to make advances (the "Advances") to Genta in a given
month on any Business Day following the determination of the Borrowing Base for
such month pursuant to Section 19.1(g), and from time to time from the Effective
Date to and including the Commitment Termination Date, each in an amount which
when added to the aggregate principal amount of all Advances

                                      -3-
<PAGE>

then outstanding and all accrued and unpaid interest thereon owed by Genta to
Aventis does not exceed the Maximum Advance. For purposes of clarification, no
Advance shall be made in a given month until the Borrowing Base for such month
has been determined in accordance with Section 19.1(g). Following the
determination of the Borrowing Base for such month, Genta may request Advances
on any Business Day for the remainder of such month, not to exceed the Maximum
Advance.

            (b) Following the determination of the Borrowing Base for a given
month, Advances shall be made at such time as Genta shall request and subject to
the conditions herein set forth, Genta may borrow, repay and reborrow amounts
constituting the Commitment.

            (c) Genta shall give Aventis prior written, telecopier or telephonic
(promptly confirmed in writing) notice of each request for an Advance hereunder
which notice shall be addressed to (*) at 400 Somerset Corporate, Mail Code SC4
525A, Bridgewater, NJ 08807-0912, facsimile no.: (*), telephone no.: (*) with a
copy to (*) at 200 Crossing Blvd, PO Box 6890, Mail Code BX2 709B, Bridgewater,
NJ 08807-6908, facsimile no.: (*), telephone no.: (*). Such notice shall be
irrevocable and to be effective, must be received by Aventis not later than 2:00
p.m., New York City time, on the fifth (5th) Business Day preceding the date on
which such Advance is to be made. Such notice shall specify (A) the amount of
the proposed Advance and (B) the date thereof (which shall be a Business Day).

            (d) Each Advance requested by Genta shall be as specified on the
applicable Borrowing Certificate delivered to Aventis in connection with such
Advance and shall be in a minimum amount of $5,000,000 (or such lesser amount as
shall equal the available but unused Commitment).

            (e) All outstanding Advances shall be payable in full on the
Maturity Date, subject to mandatory prepayment as provided in Section 19.3
hereof and acceleration as provided in Article 19.8 hereof.

            (f) From and after the Commitment Termination Date all payments
otherwise due to Genta from Aventis, including without limitation, any milestone
payments due under Section 6.2, shall be retained by Aventis and applied against
any outstanding Advances until repaid in full unless Genta provides cash
collateral in an amount equal to the outstanding Advances or other substitute
collateral which Aventis determines at such time in its sole discretion to be
satisfactory.

            (g) Within five (5) Business Days from the beginning of each
calendar month, Genta shall provide to Aventis the amount of accrued Development
Costs owing from Aventis to Genta, together with such documentation as
reasonably requested by Aventis in order to verify such Development Costs (the
"Development Cost Report"). Aventis acknowledges that such documentation may not
include all information customarily submitted by Genta with its quarterly
invoices. Within two (2) Business Days following receipt of the Development Cost
Report, Aventis shall determine the Borrowing Base in its reasonable good faith
discretion and provide Genta written notification thereof, together with a
report indicating how the Borrowing Base was calculated (the "Borrowing Base
Report"). Following the determination of the Borrowing Base

                                      -4-
<PAGE>

for any particular month, upon any changes to the applicable Over Advance Amount
as determined by Aventis in its reasonable good faith discretion, Aventis shall
provide to Genta a revised Borrowing Base Report reflecting a revised Borrowing
Base, and such revised Borrowing Base shall thereafter be the Borrowing Base
until subsequently revised as set forth herein or until a Borrowing Base is
determined for the next succeeding month. Based on receiving cooperation from
Genta, Aventis shall use good faith efforts to determine the Borrowing Base for
March 2003 by March 20, 2003.

            SECTION 19.2 Interest.

            (a) Interest shall accrue at a rate per annum (computed on the basis
of the actual number of days elapsed over a year of 360 days) equal to (*) per
annum, compounded quarterly, and shall be due and payable in one lump sum on the
Maturity Date.

            (b) Interest in respect of any Advance hereunder shall accrue from
and including the date of such Advance to but excluding the date on which such
Advance is paid, such that interest on any Advance which is prepaid in part or
in full in accordance with Section 19.3 hereof shall cease to accrue as it
relates to such part of the Advance as was prepaid on the date on which such
prepayment is made; provided, however, that interest shall continue to accrue on
(i) any portion of the Advance that was not prepaid and (ii) the balance of any
accrued but unpaid interest related to such prepaid Advance.

            (c) Anything in this Agreement to the contrary notwithstanding, the
interest rate on the Advances shall in no event be in excess of the maximum
permitted by Applicable Law.

            SECTION 19.3 Prepayments.

            (a) Genta shall have the right at its option at any time and from
time to time to prepay any Advance, in each case in whole or in part, upon at
least three (3) Business Days' prior written, telecopier or telephonic (promptly
confirmed in writing) notice to Aventis; provided, however, that, if Genta
elects to prepay any Advance in part, each such partial prepayment shall be in
the minimum amount of $1,000,000, or in the amount of the outstanding principal
amount of Advances made to Genta, together with all accrued and unpaid interest
thereon. Each notice of prepayment shall specify the prepayment date, and the
principal amount thereof, shall be irrevocable and shall commit Genta to prepay
Advances in the amount and on the date stated therein.

            (b) If at any time the aggregate principal amount of the Advances
outstanding together with all accrued and unpaid interest thereon shall exceed
the Maximum Advance, (i) Genta shall prepay Advances within 30 days to the
extent necessary to eliminate such excess and (ii) all payments otherwise due to
Genta from Aventis hereunder may, at Aventis' sole discretion, be retained by
Aventis and applied against the outstanding Advances until the aggregate
principal amount of the Advances outstanding , together with all accrued and
unpaid interest thereon are less than the Maximum Advance.

                                      -5-
<PAGE>

            SECTION 19.4 Default Interest.

            So long as an Advance Default shall have occurred and be continuing
(after, as well as before judgement), any amounts due hereunder, including
without limitation, any unpaid Advances or any accrued and unpaid interest
thereon, shall thereafter bear interest and be payable on demand at a rate equal
to the (*) per annum, compounded quarterly.

            SECTION 19.5 Manner of Payments.

            All payments by Genta hereunder shall be made without offset or
counterclaim in Dollars in Federal or other immediately available funds to such
account as Aventis may designate in writing, no later than 12:00 noon, New York
City time, on the date on which such payment shall be due. Any payment received
at such office after such time shall be deemed received on the following
Business Day. All payments on account of the Advances shall be applied first to
payment of all fees and expenses, including collection costs, due to Aventis
hereunder or under the Security Agreement, next toward payment of interest due
on the unpaid principal balance hereof, and the remainder, if any, to the
principal due hereunder.

            SECTION 19.6 Conditions Precedent to Each Advance.

            The obligation of Aventis to make each Advance is subject to the
following conditions precedent:

            (a) Notice. Aventis shall have received a notice with respect to
such borrowing as required by Section 19.1 hereof.

            (b) Representations and Warranties. The representations and
warranties set forth in Article 17 hereof and in the Security Agreement (each as
supplemented or qualified on or prior to the date by written information
communicated by Genta to Aventis) shall be true and correct in all material
respects on and as of the date of each borrowing hereunder (except to the extent
that such representations and warranties expressly relate to an earlier date)
with the same effect as if made on and as of such date.

            (c) No Advance Default. On the date of the making of each Advance
hereunder, Genta shall be in compliance with all of the terms and provisions set
forth herein and in the Security Agreement on their part to be observed or
performed, and no Advance Default shall have occurred and be continuing, nor
shall any Advance Default occur by reason of the making of such Advance.

            (d) Borrowing Certificate. On the date of the making of each Advance
hereunder, Aventis shall have received a borrowing certificate, substantially in
the form of Exhibit B to the First Amendment to the U.S. Commercialization
Agreement, executed by those Persons contemplated by such Exhibit B. Any such
certificate shall be referred to herein as a "Borrowing Certificate".

                                      -6-
<PAGE>

            (e) Additional Documents. Aventis shall have received from Genta on
the date of each borrowing such documents and information as it may reasonably
request relating to the satisfaction of the conditions in this Section 19.6.

Each borrowing shall be deemed to be a representation and warranty by Genta on
the date of such borrowing as to the matters specified in paragraphs (b) and (c)
of this Section 19.6.

            SECTION 19.7 Covenants of Genta Relating to the Advance.

            Genta covenants and agrees that until payment in full of the
principal of and interest on the Advances, it will:

            (a) Do or cause to be done all things necessary to preserve, renew
and keep in full force and effect its corporate existence, rights, licenses,
permits and franchises, and comply with all applicable statutes, regulations and
orders of, and all applicable restrictions imposed by, any Governmental
Authority, except to the extent that any such failure to act or comply would not
result in a material adverse effect on Genta's property, assets, liabilities,
business or operations. Notwithstanding the foregoing, nothing contained in this
Section 19.7(a) shall limit or otherwise modify any other covenants or
agreements of Genta set forth in any other provisions in this Agreement;

            (b) At least 30 days before the beginning of each Calendar Quarter,
deliver to Aventis a report showing in reasonable detail Genta's expected
Development Costs next two Calendar Quarters which report shall be in a form
reasonably acceptable to Aventis;

            (c) Within 5 Business Days after the beginning of each calendar
month, deliver to Aventis the Development Cost Report.

            (d) Not incur, create, assume or suffer to exist any lien on the
Collateral except for Permitted Liens (as such term is defined in the Security
Agreement); and

            (d) Not change its state of incorporation unless (i) it provides
Aventis 45 days' prior written notice of its intention to do so and provides
Aventis with any other information in connection therewith as Aventis may
request and (ii) it shall have taken all actions reasonably requested by Aventis
to maintain the security interests granted to Aventis under the Security
Agreement.

            SECTION 19.8 Advance Default.

            In the case of the happening and during the continuance of any of
the following events (herein called "Advance Default"):

            (a) Genta shall have materially breached any of its representations
or warranties hereunder, under the Security Agreement, under the Ex-U.S.
Commercialization Agreement or under the Global Supply Agreement;

                                      -7-
<PAGE>

            (b) Genta shall have materially breached or defaulted in the
performance of any of its covenants or agreements hereunder, under the Security
Agreement, under the Ex-U.S. Commercialization Agreement or under the Global
Supply Agreement;

            (c) default shall be made in the payment of principal of the
Advances or of interest on the Advances as and when due and payable;

            (d) default in payment shall be made with respect to any
indebtedness of Genta in excess of (*), when due, or in the performance of any
other obligation incurred in connection with any indebtedness of Genta in excess
of (*), if the effect of such default is to accelerate the maturity of such
indebtedness, and such default shall not be remedied, cured, waived or consented
to within the period of grace with respect thereto. For purposes of this Section
19.8(d), the term "indebtedness" shall mean: (i) all obligations for borrowed
money, (ii) all amounts evidenced by bonds, debentures, notes or other similar
instruments, (iii) all obligations to pay the deferred purchase price of goods,
property or services, including trade payables (except to the extent any amount
owing in connection with a trade payable is being diligently contested in good
faith and reasonable reserves related thereto have been established), (iv) all
obligations secured by a lien on assets, (v) capital lease obligations, or (vi)
all other indebtedness which would be included as a liability in a balance sheet
in accordance with generally accepted accounting principles;

            (e) Genta shall generally not pay its debts as they become due or
shall admit in writing its inability to pay its debts, or shall make a general
assignment for the benefit of creditors; or Genta shall commence any case,
proceeding or other action seeking to have an order for relief entered on its
behalf as debtor or to adjudicate it a bankrupt or insolvent or seeking
reorganization, arrangement, adjustment, liquidation, dissolution or composition
of it or its debts under any law relating to bankruptcy, insolvency,
reorganization or relief of debtors or seeking appointment of a receiver,
trustee, custodian or other similar official for it or for all or any
substantial part of its property or shall file an answer or other pleading in
any such case, proceeding or other action admitting the material allegations of
any petition, complaint or similar pleading filed against it or consenting to
the relief sought therein; or Genta shall take any action to authorize or in
contemplation of any of the foregoing;

            (f) any involuntary case, proceeding or other action against Genta
shall be commenced seeking to have an order for relief entered against it as
debtor or to adjudicate it a bankrupt or insolvent, or seeking reorganization,
arrangement, adjustment, liquidation, dissolution or composition of it or its
debts under any law relating to bankruptcy, insolvency, reorganization or relief
of debtors, or seeking appointment of a receiver, trustee, custodian or other
similar official for it or for all or any substantial part of its property, and
such case, proceeding or other action (i) results in the entry of any order for
relief against it or (ii) shall remain undismissed for a period of sixty (60)
days;

            (g) final judgment(s) for the payment of money in excess of (*)
(which judgment(s) is not covered by insurance) shall be rendered against Genta
and within sixty (60) days from the entry of such judgment shall not have been
discharged or stayed pending appeal or

                                      -8-
<PAGE>

shall not have been discharged within sixty (60) days from the entry of a final
order of affirmance on appeal;

            (h) (*) or

            (j) Genta shall have repudiated its obligations thereunder;

then, in every such event and at any time thereafter during the continuance of
such event, Aventis may take either or both of the following actions, at the
same or different times: terminate forthwith the Commitment and/or declare the
principal of and the interest on the Advances and all other amounts payable
hereunder to be forthwith due and payable, whereupon the same shall become and
be forthwith due and payable, without presentment, demand, protest, or other
notice of any kind, all of which are hereby expressly waived, anything in this
Agreement to the contrary notwithstanding; provided that with respect to any
event referenced in Section 19.8(b) above that by its nature is capable of cure,
Genta shall have 30 days to cure such event after delivery of written notice by
Aventis of such event, and until such 30 days have elapsed such event shall not
constitute an Advance Default. Such remedies shall be in addition to any other
remedy available to Aventis pursuant to Applicable Law or otherwise.

            SECTION 19.9 Additional Remedies Upon An Advance Default.

            Notwithstanding anything to the contrary in the Global Supply
Agreement, upon the occurrence of an Advance Default, in addition to the other
remedies herein set forth or available to Aventis pursuant to Applicable Law or
otherwise, Aventis may, in its sole discretion, issue a firm purchase order for
Finished Product, Bulk Drug Product and/or API (as each such term is defined in
the Global Supply Agreement) in a quantity equal to the lesser of (i) the amount
of inventory of Finished Product, Bulk Drug Product or API, as applicable, owned
by Genta and (ii) the quantity valued at an amount equal to any outstanding
Advances hereunder plus any accrued and unpaid interest; provided that such
Finished Product, Bulk Drug Product and/or API shall be valued for purposes
hereof in accordance with the terms of the Global Supply Agreement and shall be
deemed to satisfy any such Advance (plus interest) with respect to such value.

            Section 3. Conditions to Effectiveness. The effectiveness of this
Amendment is subject to the satisfaction of all of the following conditions
precedent (the date on which all such conditions have been satisfied being
herein called the "Effective Date"):

                  (a) Aventis shall have received with respect to Genta:

                        (i) a copy of Genta's certificate of incorporation,
            certified as of a recent date by the Secretary of State of Delaware;

                        (ii) a certificate of the Secretary of State of
            Delaware, dated as of a recent date as to the good standing of, and
            payment of taxes by, Genta, which certificate lists the charter
            documents on file in the office of such Secretary of State;

                                      -9-
<PAGE>

                        (iii) a certificate dated as of a recent date as to the
            good standing of Genta, issued by the Secretary of State of each
            jurisdiction in which Genta is qualified as a foreign corporation;

                        (iv) a certificate of the Secretary of Genta dated the
            date of the initial Advance and certifying (A) that attached thereto
            is a true and complete copy of the By-Laws of Genta as in effect on
            the date of such certification, (B) that attached thereto is a true
            and complete copy of resolutions duly adopted by the Board of
            Directors of Genta authorizing the borrowings hereunder and the
            execution, delivery and performance in accordance with their terms
            of this U.S. Commercialization Agreement and the Security Agreement
            and any other documents required or contemplated hereunder or
            thereunder to which Genta is a party, (C) that attached thereto is a
            true and complete copy of the Certificate of Incorporation of Genta
            and that the Certificate of Incorporation of Genta has not been
            amended since the date of the last amendment thereto indicated on
            the certificate of the Secretary of State furnished pursuant to
            clause (i) above except to the extent specified in such Secretary's
            Certificate and (D) as to the incumbency and specimen signature of
            each officer of Genta executing this U.S. Commercialization
            Agreement and the Security Agreement or any other document delivered
            by Genta in connection herewith or therewith (such certificate to
            contain a certification by another officer of Genta as to the
            incumbency and signature of the officer signing the certificate
            referred to in this clause (iv));

                        (v) such additional supporting documents as Aventis or
            its counsel may reasonably request;

            (b) Aventis shall have received a fully executed Security Agreement;

            (c) Aventis shall have received the favorable written opinion, dated
the date of the first Advance hereunder, addressed to Aventis of Wilson Sonsini
Goodrich & Rosati, PC, counsel to Genta, in form and substance satisfactory to
Aventis; and

            (d) the receipt by Aventis of counterparts of this Amendment which,
when taken together, bear the signatures of Aventis and Genta.

            Section 4. Representations and Warranties. Genta represents and
warrants that:

            (a) after giving effect to this Amendment, the representations and
warranties contained in the U.S. Commercialization Agreement are true and
correct in all material respects on and as of the date hereof as if such
representations and warranties had been made on and as of the date hereof
(except to the extent that any such representations and warranties specifically
relate to an earlier date); and

            (b) after giving effect to this Amendment, no Advance Default will
have occurred and be continuing on and as of the date hereof.

                                      -10-
<PAGE>

            Section 5. Further Assurances. At any time and from time to time,
upon Aventis's request and at the sole expense of Genta, Genta will promptly and
duly execute and deliver any and all further instruments and documents and take
such further action as Aventis reasonably deems necessary to effect the purposes
of this Amendment.

            Section 6. Full Force and Effect. Except as expressly amended
hereby, the U.S. Commercialization Agreement shall continue in full force and
effect in accordance with the provisions thereof on the date hereof. As used in
the U.S. Commercialization Agreement, the terms "Agreement", "this Agreement",
"herein", "hereafter", "hereto", "hereof", and words of similar import, shall,
unless the context otherwise requires, mean the U.S. Commercialization Agreement
as amended by this Amendment.

            Section 7. APPLICABLE LAW. THIS AMENDMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

            Section 8. Counterparts. This Amendment may be executed in two or
more counterparts, each of which shall constitute an original, but all of which
when taken together shall constitute but one instrument.

            Section 9. Headings. The headings of this Amendment are for the
purposes of reference only and shall not affect the construction of or be taken
into consideration in interpreting this Amendment.

                                      -11-
<PAGE>

            IN WITNESS WHEREOF, the parties hereto have caused this Amendment to
be duly executed as of the day and the year first written.

                                                GENTA INCORPORATED

                                                By______________________________
                                                    Name:
                                                    Title:

                                                AVENTIS PHARMACEUTICALS INC.

                                                By______________________________
                                                    Name:
                                                    Title:

                                      -12-
<PAGE>

                                   Exhibit A

                               Security Agreement

<PAGE>

                                    Exhibit B

                              Borrowing Certificate

<PAGE>

                          FORM OF BORROWING CERTIFICATE

      The undersigned HEREBY CERTIFIES with respect to the Advances to be made
on the date indicated below pursuant to the U.S. Commercialization Agreement
dated as of April 26, 2002 between Genta Incorporated ("Genta") and Aventis
Pharmaceuticals Inc. ("Aventis") as amended by Amendment No. 1 dated as of March
14, 2003 (as the same may be further amended, supplemented or otherwise
modified, the "U.S. Commercialization Agreement; capitalized terms used herein
and not otherwise defined shall have the meanings set forth in the U.S.
Commercialization Agreement) that:

            (a) the representations and warranties contained in Article 17 of
      the U.S. Commercialization Agreement and in the Security Agreement (each
      as supplemented or qualified on or prior to the date hereof by written
      information communicated by Genta to Aventis) are true and correct in all
      material respects on and as of the date hereof as if such representations
      and warranties had been made on and as of the date hereof (except to the
      extent that such representations and warranties expressly relate to an
      earlier date) with the same effect as if made on and as of such date;

            (b) no default or Advance Default has occurred or is continuing, nor
      shall any such default or Advance Default occur by reason of the making of
      the Advance requested herein;

            (c) Genta requests an Advance on the terms and conditions as stated
      in the U.S. Commercialization Agreement:

                  (i) the requested Business Day of the Advance is ____________;

                  (ii) the amount of the requested Advance is $________________;

            (d) The undersigned has no reason to believe that the lesser of the
      Borrowing Base if currently computed and the Commitment would be less than
      the sum of the outstanding principal amount of all Advances plus all
      accrued interest thereon owed by Genta to Aventis under the U.S.
      Commercialization Agreement (after giving effect to the Advance requested
      hereby).

      IN WITNESS WHEREOF, the undersigned has caused this certificate to be
executed this ____ day of ________, _____.

                                                  GENTA INCORPORATED.

                                                  By____________________________
                                                    Name:
                                                    Title:Exhibit 10.23

                               TELULAR CORPORATION
                         COMMON STOCK PURCHASE AGREEMENT

     THIS COMMON STOCK PURCHASE AGREEMENT (this "Agreement") is made and entered
into as of April 14, 2003 by and among Telular Corporation, a Delaware
corporation (the "Company"), and QUALCOMM Incorporated, a Delaware corporation
(the "Investor").

     1.   AGREEMENT TO PURCHASE AND SELL STOCK.

          1.1  Authorization. As of the Closing (as defined below) the Company
will have authorized the issuance, pursuant to the terms and conditions of this
Agreement, shares of the Company's Common Stock, $.001 par value, (the "Common
Stock") representing a value of one million dollars ($1,000,000) at the price
per share calculated pursuant to the formula specified at Section 1.3 below.

          1.2  Agreement to Purchase and Sell. The Company agrees to sell to
Investor at the Closing, and the Investor agrees to purchase from the Company at
the Closing, the number of shares of Common Stock representing a value of one
million dollars ($1,000,000) at the price per share calculated pursuant to the
formula specified at Section 1.3 below. The shares of Common Stock purchased and
sold pursuant to this Agreement will be collectively hereinafter referred to as
the "Purchased Shares."

          1.3  Price Per Share. The price per share to be paid by Investor for
the Purchased Shares shall be calculated by taking the lesser of (a) the ten
(10) day trailing average of the closing price for the Company's shares as
quoted on the NASDAQ national market for the ten (10) days preceding the
Effective Date (as defined in the CDMA Agreement) of the Fixed Wireless CDMA
Subscriber Unit License Agreement (the "CDMA Agreement") or (b) the ten (10) day
trailing average of the closing price for the Company's shares as quoted on the
NASDAQ national market for the ten (10) days preceding the date of the Closing.

     2.   CLOSING.

          2.1  The Closing. The purchase and sale of the Purchased Shares will
take place at the offices of Investor, 5775 Morehouse Dr., San Diego, CA 92121,
at 10:00 AM local San Diego time on April 14, 2003, or at such other time and
place as the Company and the Investor mutually agree upon (which time and place
are referred to in this Agreement as the "Closing"). At the Closing, the Company
will deliver to the Investor a certificate representing the number of Purchased
Shares that such Investor has agreed to purchase hereunder against payment of
the purchase price therefore by contribution of the $1,000,000 debt owing from
the Company to Investor in connection with the licensing of Investor's
technology and the CDMA Agreement.

     3.   REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby
represents and warrants to the Investor that, except as set forth in the
Disclosure Schedule (the "Disclosure Schedule") separately delivered by the
Company to the Investor (which Disclosure Schedule shall be deemed to be
representations and warranties to the Investor by the Company under this Section
and to qualify each of the representations and warranties set forth herein), the
statements in the following paragraphs of this Section 3 are all true and
correct:

<PAGE>

                                     - 2 -

          3.1  Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware, and has all requisite corporate power and authority to
conduct its business as currently conducted. The Company is qualified to do
business as a foreign corporation in each jurisdiction where failure to be so
qualified could reasonably be expected to have a material adverse effect on the
business, assets, financial condition or results of operations or assets of the
Company (the "Business") (such effect referred to as a "Material Adverse
Effect").

          3.2  Capitalization. Immediately before the Closing the capitalization
of the Company will consist of the following:

               (a)  Preferred Stock. A total of 9,979,000 authorized shares of
Preferred Stock, $.001 par value per share (the "Preferred Stock"), none of
which are issued and outstanding.

               (b)  Common Stock. A total of 75,000,000 authorized shares of
Common Stock, of which approximately 12,820,421 shares were issued and
outstanding as of March 31, 2003. There are no stockholder agreements, voting
agreements or other similar agreements with respect to the Common Stock to which
the Company is a party.

               (c)  Options, Warrants, Reserved Shares. Except for: (i) 300,000
shares of Common Stock reserved for issuance under the Company's Non-employee
Director Stock Option Plan, (ii) 2,850,000 additional shares of Common Stock
reserved for issuance under the Company's Employee Stock Purchase Plan, (iii)
warrants to purchase an aggregate of 283,407 shares of Common Stock issued to
Palladin Group, (iv) a warrant to purchase 75,000 shares of Common Stock issued
to Cardinal Securities, (v) a warrant to purchase 50,000 shares of Common Stock
issued to Wells Fargo Business Credit, Inc., all outstanding as of March 31,
2003, there are not outstanding any options, warrants, rights or agreements for
the purchase or acquisition from the Company of any shares of its capital stock
or any securities convertible into or ultimately exchangeable or exercisable for
any shares of the Company's capital stock.

          3.3  Subsidiaries. Except for the subsidiaries of the Company listed
on the Disclosure Schedule, the Company does not presently own or control,
directly or indirectly, any interest in any other corporation, partnership,
trust, joint venture, association, or other entity.

          3.4  Due Authorization; No Violation. All corporate action on the part
of the Company and its officers, directors and stockholders necessary for the
authorization, execution and delivery of, and the performance of all obligations
of the Company under, this Agreement, and the authorization, issuance,
reservation for issuance and delivery of all of the Purchased Shares being sold
under this Agreement, has been taken or will be taken prior to the Closing, and
this Agreement constitutes a valid and legally binding obligation of the
Company, enforceable against the Company in accordance with its terms, except as
enforceability may be limited by (i) applicable bankruptcy, insolvency,
reorganization or other laws of general application relating to or affecting the
enforcement of creditors' rights generally and (ii) the effect of rules of law
governing the availability of equitable remedies. Neither the execution,
delivery or performance by the Company of this Agreement nor the consummation by
the Company of the transactions contemplated hereby will (i) conflict with or
result in a breach of any provision of the Company's Certificate of
Incorporation or the Company's Bylaws, (ii) conflict with, result in a violation
or breach of, or cause a default (or give rise to any right of termination,
cancellation or acceleration) under any of the terms, conditions or provisions
of any agreement, instrument or obligation to which the Company is a party,
which default could reasonably be expected to have a Material Adverse Effect or
(iii) violate any law, statute, rule or regulation or judgment, order, writ,
injunction or decree of any governmental authority, in each case applicable to
the Company or its

<PAGE>

                                      - 3 -

properties or assets and which, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect.

          3.5  Valid Issuance of Stock. The Purchased Shares, when issued, sold
and delivered in accordance with the terms of this Agreement for the
consideration provided for herein, will be duly and validly issued, fully paid
and nonassessable and are not subject to preemptive or other similar rights of
any stockholder of the Company.

          3.6  Governmental Consents. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state or local governmental authority on the part of
the Company is required in connection with the valid execution and delivery of
this Agreement, the offer, sale and issuance of the Purchased Shares, or the
consummation of the transactions contemplated by this Agreement, except for
qualifications or filings under the Securities Act of 1933, as amended (the
"Act") and the applicable rules and regulations (the "Rules and Regulations") of
the Securities and Exchange Commission (the "Commission") under the Act, and all
other applicable securities laws as may be required in connection with the
transactions contemplated by this Agreement. All such qualifications will be
effective on the Closing, and all such filings be made within the time
prescribed by law.

          3.7  Absence of Changes. After the respective dates as of which
information is given in the Company's Proxy Statement for the annual meeting of
stockholders held on January 28, 2003, the Company's Annual Report on Form 10-K
for the period ended September 30, 2002, and the Company's Quarterly Report on
Form 10-Q for the quarter ended December 31, 2002, respectively (such documents,
together with the Disclosure Schedule, referred to collectively as the
"Disclosure Documents"), except as set forth on the Disclosure Schedule, there
has not been (i) any change in the Business that to the knowledge of the Company
constitutes a Material Adverse Effect, (ii) any obligation of the Company,
direct or contingent, in excess of $1,000,000, other than in the ordinary course
of business, (iii) any increase in excess of $100,000 in the outstanding
indebtedness for borrowed money of the Company, (iv) any dividend declared, paid
or made on the capital stock of the Company, (v) any loss or damage (whether or
not insured) to the property of the Company which has been sustained which could
reasonably be expected to have a Material Adverse Effect, or (vi) any material
change in the accounting methods or practices followed by the Company.

          3.8  Litigation. Except as set forth in the Disclosure Documents,
there is no action, suit, proceeding, claim, arbitration or investigation
("Action") pending (or, to the Company's knowledge, currently threatened)
against the Company, its activities, properties or assets, which (i) might
prevent the consummation of the transactions contemplated hereby or (ii) could
reasonably be expected to have a Material Adverse Effect.

          3.9  Nasdaq Listing. The Common Stock is registered pursuant to
Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and is listed on the Nasdaq Stock Market (Nasdaq National Market). The
Company has not received any notification that the Commission or the National
Association of Securities Dealers, Inc. is contemplating the termination of such
registration or listing.

          3.10 Exchange Act Filings. The Company has filed in a timely manner
all reports and other information required to be filed ("Filings") with the
Commission pursuant to the Exchange Act during the preceding twelve calendar
months. On their respective dates of filing, the Filings complied as to form in
all material respects with the requirements of the Exchange Act, and the
published rules and regulations of the Commission promulgated thereunder. On
their respective dates of filing, the Filings did not include any untrue
statement of a material fact required to be stated therein or necessary to make

<PAGE>

                                     - 4 -

the statements therein, in light of the circumstances in which they were made,
not misleading, and all financial statements contained in the Filings fairly
present the financial position of the Company on the dates of such statements
and the results of operations for the periods covered thereby in accordance with
generally accepted accounting principles consistently applied throughout the
periods involved and prior periods, except as otherwise indicated in the notes
to such financial statements.

          3.11 Disclosure. The representations and warranties made by the
Company in this Agreement (including the Disclosure Schedule) and the Filings
when read together do not contain any untrue statement of a material fact and do
not omit to state a material fact necessary to make the statements herein and
therein as a whole not misleading.

          3.12 Governmental Permits, Etc. The Company possesses all licenses,
franchises, governmental approvals, permits or other governmental authorizations
(collectively, "Authorizations") relating to the operation of the Business,
except for those Authorizations the failure of which to possess would not,
separately or in the aggregate, have a Material Adverse Effect. To the Company's
knowledge, the Company is in compliance with the terms of all Authorizations and
all laws, ordinances, regulations and decrees which to the Company's knowledge
are applicable to the Business, except for such non-compliance which does not,
separately or in the aggregate, have a Material Adverse Effect.

          3.13 Insurance. The Company is covered by insurance with companies the
Company believes to be responsible and in such amounts and covering such risks
as it believes to be adequate for the conduct of its Business and the value of
its properties and which, it believes, is customary for companies engaged in
similar businesses in similar industries. The Company has no knowledge that any
such carrier has grounds or intends to cancel or fail to renew such policies.

          3.14 Intellectual Property. The Company owns or possesses the patents,
patent rights, licenses, inventions, copyrights, know-how (including trade
secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) and other rights or interests in items of
intellectual property that are necessary for the operation of the Business as
currently operated by it (the "Patent and Proprietary Rights"), except where the
failure to own or possess such rights would not have a Material Adverse Effect;
the Company has not received notice of any asserted rights with respect to any
of the Patent and Proprietary Rights which, if determined unfavorably with
respect to the interests of the Company would have a Material Adverse Effect;
and the Company has not received notice or is otherwise aware of any
infringement of or conflict with asserted rights of others with respect to any
of the Patent or Proprietary Rights, which infringement or conflict (if the
subject of any unfavorable decision, ruling or finding), individually or in the
aggregate, would result in a Material Adverse Effect.

          3.15 Employees. The Company is not aware that any officer or key
employee, or that any group of key employees, intends to terminate their
employment with the Company, nor does the Company have any present intention to
terminate the employment of any officer, key employee or group of key employees.

     4.   REPRESENTATIONS, WARRANTIES AND CERTAIN AGREEMENTS OF INVESTORS. The
Investor hereby represents and warrants to, and agrees with, the Company, that:

          4.1  Authorization. All corporate action on the part of the Investor
and its officers, directors and stockholders necessary for the authorization,
execution and delivery of, and the performance of all obligations of the
Investor under, this Agreement has been taken or will be taken prior to the
Closing, and this Agreement constitutes a valid and legally binding obligation
of the Investor, enforceable against the Investor in accordance with its terms,
except as enforceability may be limited by (i) applicable bankruptcy,
insolvency, reorganization or other laws of general application relating to or
affecting the

<PAGE>

                                     - 5 -

enforcement of creditors' rights generally and (ii) the effect of rules of law
governing the availability of equitable remedies.

          4.2  Purchase for Own Account. The Purchased Shares to be purchased by
such Investor hereunder will be acquired for investment for such Investor's own
account, not as a nominee or agent, and not with a view to the public resale or
distribution thereof within the meaning of the Act, and such Investor has no
present intention of selling, granting any participation in, or otherwise
distributing the same. If not an individual, such Investor also represents that
such Investor has not been formed for the specific purpose of acquiring
Purchased Shares.

          4.3  Disclosure of Information. The Investor has received a copy of
the Disclosure Documents and has received or has had full access to all the
information it considers necessary or appropriate to make an informed investment
decision with respect to the Purchased Shares to be purchased by the Investor
under this Agreement. Investor further has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the
offering of the Purchased Shares and to obtain additional information (to the
extent the Company possessed such information or could acquire it without
unreasonable effort or expense) necessary to verify any information furnished to
the Investor or to which the Investor had access. The foregoing, however, does
not in any way limit or modify the representations and warranties made by the
Company in Section 3.

          4.4  Investment Experience. Such Investor understands that the
purchase of the Purchased Shares involves substantial risk. Such Investor has
experience as an investor in securities of companies in the development stage
and acknowledges that such Investor is able to fend for itself, can bear the
economic risk of such Investor's investment in the Purchased Shares and has such
knowledge and experience in financial or business matters that such Investor is
capable of evaluating the merits and risks of this investment in the Purchased
Shares and protecting its own interests in connection with this investment.

          4.5  Accredited Investor Status. The Investor is an "accredited
investor" within the meaning of Regulation D promulgated under the Act.

          4.6  Restricted Securities. The Investor understands that the
Purchased Shares are characterized as "restricted securities" under the Act
inasmuch as they are being acquired from the Company in a transaction not
involving a public offering and that under the Act and the Rules and Regulations
such securities may be resold without registration under the Act only in certain
limited circumstances. In this connection, the Investor represents that such
Investor is familiar with Rule 144 of the Commission and understands the resale
limitations imposed thereby and by the Act. The Investor understands that the
Company is under no obligation to register any of the Purchased Shares except as
provided in Section 7 below.

          4.7  Further Limitations on Disposition. Without in any way limiting
the representations set forth above, the Investor further agrees not to make any
disposition of all or any portion of the Purchased Shares unless and until:

               (a)  there is then in effect a registration statement under the
Act covering such proposed disposition and such disposition is made in
accordance with such registration statement and the provisions of Section 7 of
this Agreement; or

               (b)  (i) the Investor shall have notified the Company of the
proposed disposition and shall have furnished the Company with a statement of
the circumstances surrounding the proposed disposition, and (ii) the Investor
shall have furnished the Company, at the expense of the

<PAGE>

                                     - 6 -

Investor or its transferee, with an opinion of counsel, reasonably satisfactory
to the Company, that such disposition will not require registration of such
securities under the Act.

          Notwithstanding the provisions of paragraphs (a) and (b) above, no
such registration statement or opinion of counsel shall be required: (i) for any
routine transfer of any Purchased Shares in compliance with Rule 144 or Rule
144A (except that an opinion of counsel may be required for other than routine
Rule 144 transactions), or (ii) for any transfer of Purchased Shares by an
Investor that is a partnership or a corporation to (A) a partner of such
partnership or stockholder of such corporation, or (B) the estate of any such
partner or stockholder, or (iii) for the transfer by gift, will or intestate
succession by the Investor to his or her spouse or lineal descendants or
ancestors or any trust for any of the foregoing; provided, that in each of the
foregoing cases the transferee agrees in writing to be subject to the terms of
this Section 4 (other than Section 4.5) to the same extent as if the transferee
were an original Investor hereunder.

          4.8  Legends. It is understood that the certificate evidencing the
Purchased Shares will bear the legends set forth below:

               (a)  THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS
ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS
PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE
REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD
OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED
TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS.

               (b)  THE SHARES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO THE
PROVISIONS OF, AND MAY HAVE CERTAIN REGISTRATION RIGHTS PURSUANT TO, THE
PROVISIONS OF A PURCHASE AGREEMENT BETWEEN THE COMPANY AND THE HOLDER, WHICH MAY
RESTRICT THE TRANSFER OF SUCH SHARES IN CERTAIN CIRCUMSTANCES. A COPY OF SUCH
AGREEMENT MAY BE OBTAINED, WITHOUT CHARGE, AT THE COMPANY'S PRINCIPAL OFFICE.

               (c)  After consultation with counsel for the Investor, any legend
that counsel to the Company reasonably deems appropriate under the laws of the
State of Delaware.

     The legends set forth in (a) and (b) above shall, upon the request of an
Investor, be promptly removed by the Company from any certificate evidencing
Purchased Shares upon delivery to the Company of an opinion of counsel to the
Company that the legended security can be freely transferred in a public sale
without a registration statement being in effect under the Act and in compliance
with exemption requirements under applicable state securities laws and that such
transfer will not jeopardize the exemption or exemptions from registration
pursuant to which the Company issued the Purchased Shares; provided, however,
that no such opinion shall be required in connection with routine sales of
Purchased Shares pursuant to the Shelf Registration Statement (as defined
below). In connection with any such opinion, the Investor shall provide such
certifications as may reasonably be deemed necessary for the delivery of such
opinion.

<PAGE>

                                     - 7 -

     5.   CONDITIONS TO INVESTOR'S OBLIGATIONS AT CLOSING.

          5.1  Closing. The obligations of the Investor under Section 2 of this
Agreement to purchase the Purchased Shares at the Closing are subject to the
fulfillment or waiver, on or before the Closing, of each of the following
conditions, and the Company shall use all reasonable efforts to cause such
conditions to be satisfied on or before the Closing:

               5.1.1 Representations and Warranties True. Each of the
representations and warranties of the Company contained in Section 3 shall be
true and correct in all material respects on and as of the Closing with the same
effect as though such representations and warranties had been made on and as of
the Closing.

               5.1.2 Performance. The Company shall have performed and complied
in all material respects with all agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with
by it on or before the Closing and shall have obtained all approvals, consents
and qualifications necessary to complete the purchase and sale described herein.

               5.1.3 Compliance Certificate. The Company shall have delivered to
the Investors at the Closing a certificate signed on its behalf by its President
or Chief Executive Officer certifying that the conditions specified in Sections
5.1.1 and 5.1.2 have been fulfilled.

               5.1.4 Registration; Securities Exemptions. The offer and sale of
the Purchased Shares to the Investor pursuant to this Agreement shall be exempt
from the registration requirements under the Act, as amended, and the rules
thereunder and the registration and/or qualification requirements of all other
applicable state securities laws (the "Law").

               5.1.5 No Material Change. There shall have been no material
adverse change in the Business from the date of this Agreement.

               5.1.6 Opinion of Counsel. The Investors shall have received an
opinion of counsel to the Company substantially in the form of Exhibit A
attached hereto.

     6.   CONDITIONS TO THE COMPANY'S OBLIGATIONS AT CLOSING.

          6.1  Closing. The obligations of the Company under this Agreement to
sell the Purchased Shares to the Investor at the Closing are subject to the
fulfillment or waiver on or before the Closing of each of the following
conditions by the Investor, and the Investor shall use all reasonable efforts to
cause such conditions to be satisfied on or before the Closing:

               6.1.1 Representations and Warranties. The representations and
warranties of the Investor contained in Section 4 shall be true and correct in
all material respects on and as of the Closing with the same effect as though
such representations and warranties had been made on and as of the Closing.

               6.1.2 Payment of Purchase Price. The Investor shall have
delivered to the Company the purchase price for the Purchased Shares specified
in Section 2.

               6.1.3 Registration; Securities Exemptions. The offer and sale of
the Purchased Shares to the Investor pursuant to this Agreement shall be exempt
from the registration requirements under the Act and shall be exempt from the
qualification requirements of the Law and the registration and/or qualification
requirements of all other applicable state securities laws.

<PAGE>

                                     - 8 -

     7.   REGISTRATION RIGHTS.

          7.1  Definitions. For purposes of this Agreement:

               (a)  Form S-3. The term "Form S-3" means such form under the Act
as is in effect on the date hereof or any successor registration form under the
Act subsequently adopted by the Commission which permits inclusion or
incorporation of substantial information by reference to other documents filed
by the Company with the Commission.

               (b)  Holder. The term "Holders" shall mean holders of Registrable
Securities that have registration rights pursuant to this Agreement.

               (c)  Registration. The terms "register," "registered," and
"registration" refer to a registration effected by preparing and filing a
registration statement in compliance with the Act, and the declaration or
ordering of effectiveness of such registration statement.

               (d)  Registrable Securities. The term "Registrable Securities"
means: (1) all of the Purchased Shares, and (2) any shares of Common Stock of
the Company issued as a dividend or other distribution with respect to, or in
exchange for or in replacement of, any of the Purchased Shares; provided,
however, that the term "Registrable Securities" shall exclude in all events (and
such securities shall not constitute "Registrable Securities") (i) any
Registrable Securities sold or transferred by a person in a transaction in which
the registration rights granted under this Agreement are not assigned in
accordance with the provisions of this Agreement, (ii) any Registrable
Securities sold in a public offering pursuant to a registration statement filed
with the Commission or sold pursuant to Rule 144 promulgated under the Act
("Rule 144") or (iii) as to any Holder, the Registrable Securities held by such
Holder if all of such Registrable Securities can be publicly sold without volume
restriction within a three-month period pursuant to Rule 144.

               (e)  Prospectus: The term "Prospectus" shall mean the prospectus
included in any Shelf Registration Statement (including, without limitation, a
prospectus that discloses information previously omitted from a prospectus filed
as part of an effective registration statement in reliance upon Rule 430A
promulgated under the Act), as amended or supplemented by any prospectus
supplement (including, without limitation, any prospectus supplement with
respect to the terms of the offering of any portion of the Registrable
Securities covered by such Shelf Registration Statement), and all other
amendments and supplements to the Prospectus, including post-effective
amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.

               (f)  Shelf Registration Statement. See Section 7.2(a).

          7.2  Form S-3 Shelf Registration.

               (a)  Registration. The Company shall prepare and file with the
Commission within sixty (60) days following the Closing and use all reasonable
efforts to have declared effective as soon as practicable thereafter, but not
later than August 1, 2003, a registration statement on Form S-3 (or, if the
Company is not then eligible to use Form S-3, then another appropriate form)
providing for the resale by the Holders of all of the Registrable Securities
(the "Shelf Registration Statement"). The Shelf Registration Statement may
include securities other than those held by Holders. The Company shall use its
best efforts to keep the Shelf Registration Statement continuously effective
(subject to Section 7.2(b)), pursuant to the Act and the Rules and Regulations
promulgated thereunder, until (i) the date when such Registrable Securities
cease to meet the definition of Registrable Securities

<PAGE>

                                     - 9 -

pursuant to Section 7.1, or (ii) the Company's obligations hereunder terminate
(the "Permitted Window"). In the event that the Shelf Registration Statement
shall cease to be effective, the Company shall promptly prepare and file a new
registration statement covering the Registrable Securities and shall use its
best efforts to have such registration statement declared effective as soon as
possible. Any such registration statement shall be considered a "Shelf
Registration Statement" hereunder. The registration rights granted hereunder are
not subject or subordinate to any prior registration rights granted to any other
securityholder of the Company.

               (b)  Blackout Notice. In the event (i) that the Company concludes
that it is necessary for the Company to supplement the Prospectus or make an
appropriate filing under the Exchange Act so as to cause the Prospectus to
become current, or (ii) that, in the reasonable and good faith judgment of the
President, Chief Executive Officer or the Company's Board of Directors, it is
advisable to suspend use of the Prospectus for a discrete period of time due to
material undisclosed pending corporate developments or pending public filings
with the Commission (which need not be described in detail), the Company shall
deliver a written notice (the "Blackout Notice") to each Holder to the effect of
the foregoing and, upon delivery of the Blackout Notice, each Holder shall not
sell any Purchased Shares or any other securities of the Company that are held
by such Holder, shall not otherwise engage in any other Disposition with respect
to the Company's securities, and shall not disclose to any third party that such
a notice has been given or the contents of the notice. The Permitted Window
shall resume upon the Holders' receipt of copies of the supplemented or amended
Prospectus, or at such time as each Holder is advised in writing by the Company
that the Prospectus may be used, and at such time as each Holder has received
copies of any additional or supplemental filings that are incorporated or deemed
incorporated by reference in such Prospectus and which are required to be
delivered as part of the Prospectus. In any event, such restrictions shall
terminate no later than 45 days after the date of delivery of the Blackout
Notice. If the Company has delivered a Blackout Notice within 90 days of the
date that it delivers another Blackout Notice pursuant this section, then the
45-day time period set forth in the preceding sentence shall be shortened so
that the restrictions imposed by the Blackout Notice shall expire no later than
10 days after delivery of such Blackout Notice.

               (c)  Expenses. The registration fees and expenses incurred by the
Company in connection with the Shelf Registration Statement and actions taken by
the Company in connection with each Permitted Window shall be borne by the
Company. Each Holder shall be responsible for any fees and expenses of its
counsel or other advisers.

          7.3  Obligations of the Company. Whenever required to effect the
registration of any Registrable Securities under this Agreement, the Company
shall, as expeditiously as reasonably possible:

               (a)  Furnish to each Holder such number of copies of a
Prospectus, including a preliminary Prospectus, in conformity with the
requirements of the Act, and such other documents as it may reasonably request
in order to facilitate the disposition of the Registrable Securities owned by it
that are included in such registration.

               (b)  Use all reasonable efforts to register and qualify the
securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the
Holders, provided that the Company shall not be required in connection therewith
or as a condition thereto to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions.

               (c)  Notify each Holder promptly (i) of any request by the
Commission or any other federal or state governmental authority during the
period of effectiveness of a registration statement for amendments or
supplements to such registration statement or related prospectus or for

<PAGE>

                                     - 10 -

additional information, (ii) of the issuance by the Commission or any other
federal or state governmental authority of any stop order suspending the
effectiveness of a registration statement or the initiation of any proceedings
for that purpose and (iii) of the receipt by the Company of any notification
with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction
or the initiation or threatening of any proceeding for such purpose.

               (d)  Make every reasonable effort to obtain the withdrawal of any
order suspending the effectiveness of the Shelf Registration Statement at the
earliest possible time.

          7.4  Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to Section 7.2 that each
Holder shall furnish to the Company such information regarding it, the
Registrable Securities held by it, and the intended method of disposition of
such securities as shall be required to timely effect the registration of its
Registrable Securities.

          7.5  Indemnification. In the event any Registrable Securities are
included in a registration statement under this Agreement:

               (a)  By the Company. To the extent permitted by law, the Company
will indemnify and hold harmless each Holder, the officers and directors of such
Holder, each person, if any, who controls a Holder and any underwriter (as
defined in the Act) acting on behalf of a Holder (such persons and entities
referred to as "Holder Indemnified Parties"), against any losses, expenses,
damages or liabilities to which they may become subject under the Act, the
Exchange Act or other federal or state law (a "Loss"), insofar as such Losses
(or actions in respect thereof) arise out of any claim, action or proceeding
brought by a third party arising out of or based upon any of the following
statements, omissions or violations (collectively a "Violation"):

                    (i)  any untrue statement or alleged untrue statement of a
               material fact contained in a registration statement filed
               pursuant to this Section 7;

                    (ii) the omission or alleged omission to state in a
               registration statement filed pursuant to this Section 7 a
               material fact required to be stated therein, or necessary to make
               the statements therein not misleading; or

                    (iii) any violation or alleged violation by the Company of
               the Act, the Exchange Act, any federal or state securities law or
               any rule or regulation promulgated under the Act, the Exchange
               Act or any federal or state securities law, in each case in
               connection with the offering covered by such registration
               statement;

and the Company will reimburse each Holder Indemnified Party for any legal or
other expenses reasonably incurred by them, as incurred, in connection with
investigating or defending any such Violation; provided, however, that the
indemnity agreement contained in this subsection shall not apply to amounts paid
in settlement of any such Loss, if such settlement is effected without the
consent of the Company, nor shall the Company be liable in any such case for any
such Loss to the extent that it arises out of or is based upon a Violation which
occurs in reliance upon and in conformity with written information furnished
expressly for use in connection with such registration statement by the Holder
Indemnified Party; and provided further, that the Company will not be liable for
the reasonable legal fees and expenses of more than one counsel to the Holder
Indemnified Parties.

               (b)  By the Holders. To the extent permitted by law, each Holder
will indemnify and hold harmless the Company, each of its directors, each of its
officers who have signed the

<PAGE>

                                     - 11 -

registration statement, and each person, if any, who controls the Company within
the meaning of the Act (such persons and entities referred to as "Company
Indemnified Parties") against any Losses to which such Company Indemnified
Parties may become subject under the Act, the Exchange Act or other federal or
state law, insofar as such Losses (or actions in respect thereto) arise out of
or are based upon any Violation, in each case to the extent (and only to the
extent) that such Violation occurs in reliance upon and in conformity with
written information furnished by the Holders expressly for use in connection
with such registration statement; and the Holders will reimburse any legal or
other expenses reasonably incurred by such Company Indemnified Parties in
connection with investigating or defending any such Violation; provided,
however, that the indemnity agreement contained in this subsection shall not
apply to amounts paid in settlement of any such Loss if such settlement is
effected without the consent of the Holders; provided further, that the Holders
shall not be liable for the reasonable legal fees and expenses of more than one
counsel to the Company Indemnified Parties; and provided further, that the total
amounts payable in indemnity by the Holders under this subsection in respect of
any Violation shall not exceed the net proceeds received by the Holders in the
registered offering out of which such Violation arises.

               (c)  Notice. Promptly after receipt by an indemnified party under
this Section of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim for
indemnification in respect thereof is to be made against any indemnifying party
under this Section, deliver to the indemnifying party a written notice of the
commencement of such an action and the indemnifying party shall have the right
to participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel selected by the indemnifying party and reasonably
acceptable to a majority in interest of the indemnified parties; provided,
however, that an indemnified party shall have the right to retain its own
counsel, with the reasonable fees and expenses to be paid by the indemnifying
party, if the indemnified party has been advised in writing by counsel that
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual conflict of interests
between such indemnified party and any other party represented by such counsel
in such proceeding. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action shall
relieve such indemnifying party of liability to the indemnified party under this
Section to the extent such delay caused material prejudice to the indemnified
party, but the omission so to deliver written notice to the indemnifying party
will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section.

               (d)  Defect Eliminated in Final Prospectus. The foregoing
indemnity agreements of the Company and the Holders are subject to the condition
that, insofar as they relate to any Violation made in a preliminary prospectus
but eliminated or remedied in the amended prospectus on file with the Commission
at the time the registration statement in question becomes effective or in the
amended prospectus filed with the Commission pursuant to Rule 424(b) of the
Commission (the "Final Prospectus"), such indemnity agreements shall not inure
to the benefit of any person if a copy of the Final Prospectus was furnished in
a timely manner to the indemnified party and was not furnished to the person
asserting the loss, liability, claim or damage at or prior to the time such
action is required by the Act.

               (e)  Survival. The obligations of the Company and the Holder
under this Section shall survive the completion of any offering of Registrable
Securities in a registration statement, and otherwise.

          7.6  Rule 144 Reporting. With a view to making available the benefits
of certain rules and regulations of the Commission which may at any time permit
the sale of the Registrable Securities to the public without registration, for
so long as each Holder owns any Registrable Securities, the Company agrees to:

<PAGE>

                                     - 12 -

               (a)  Make and keep adequate, current public information
available, as those terms are understood and defined in Rule 144 under the Act,
at all times;

               (b)  File with the Commission in a timely manner all reports and
other documents required of the Company under the Exchange Act; and

               (c)  So long as such Holder owns any Registrable Securities, to
furnish to such Holder forthwith upon request a written statement by the Company
as to its compliance with the reporting requirements of said Rule 144, a copy of
the most recent annual or quarterly report of the Company, and such other
reports and documents of the Company as such Holder may reasonably request in
availing itself of any rule or regulation of the Commission allowing the Holder
to sell any such securities without registration.

          7.7  Termination of the Company's Obligations. The Company shall have
no obligation to register, or maintain, a registration statement governing
Registrable Securities, (i) if all Registrable Securities have been registered
and sold pursuant to registrations effected pursuant to this Agreement, or (ii)
with respect to any particular Holder, at such time as all Registrable
Securities held by such Holder may be sold without any volume restrictions
within a three month period under Rule 144, as it may be amended from time to
time, including but not limited to amendments that reduce that period of time
that securities must be held before such securities may be sold pursuant to such
rule.

          7.8  Piggyback Registrations.

               (a)  The Company shall use its best efforts to notify all Holders
of Registrable Securities in writing at least twenty (20) days before filing any
registration statement under the Act for purposes of effecting an underwritten
public offering by the Company of securities of the Company (excluding
registration statements relating to any employee benefit plan or a corporate
merger, acquisition or reorganization, or any Form S-3 or similar shelf
registration statements relating to the non-underwritten offer and sale of
securities for the account of persons or entities other than the Company) and
will afford each such Holder an opportunity to include in such registration
statement all or any part of the Registrable Securities then held by such
Holder. Each Holder desiring to include in any such registration statement all
or any part of the Registrable Securities held by such Holder shall, within ten
(10) days after receipt of the above-described notice from the Company, so
notify the Company in writing, and in such notice shall inform the Company of
the number of Registrable Securities such Holder wishes to include in such
registration statement. If a Holder decides not to include all of its
Registrable Securities in any such registration statement filed by the Company,
such Holder shall nevertheless continue to have the right to include any
Registrable Securities in any subsequent registration statement or registration
statements as may be filed by the Company with respect to offerings of its
securities, all upon the terms and conditions set forth herein. The Holders'
rights to include any Registrable Securities in any offering under this Section
are subject in all events to the ability of the managing underwriter for such
offering to exclude some or all of the Registrable Securities requested to be
registered on the basis of a good faith determination that inclusion of such
securities might adversely affect the success of the offering or otherwise
adversely affect the Company. Any such exclusion shall be pro rata among all
Holders who have requested to sell Registrable Securities in such registration.

               (b)  Underwriting. If a registration statement under which the
Company gives notice under this Section is for an underwritten offering, then
the Company shall so advise the Holders of Registrable Securities. In such
event, the right of any such Holder's Registrable Securities to be included in a
registration pursuant to this Section shall be conditioned upon such Holder's
participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting to the extent provided herein. All
Holders proposing to distribute their Registrable Securities through such

<PAGE>

                                     - 13 -

underwriting shall enter into an underwriting agreement in customary form with
the managing underwriter or underwriters selected for such underwriting and
shall furnish such information and documents as the Company or the managing
underwriter or underwriters may reasonably request. Notwithstanding any other
provision of this Agreement, if the managing underwriter determine(s) in good
faith that marketing factors require a limitation of the number of shares to be
underwritten, then the managing underwriter(s) may exclude Registrable
Securities from the registration and the underwriting, pro rata among all
Holders who have requested to sell Registrable Securities in such registration.
If any Holder disapproves of the terms of any such underwriting, such Holder may
elect to withdraw therefrom by written notice to the Company and the
underwriter, delivered at least ten (10) business days prior to the effective
date of the registration statement. Any Registrable Securities excluded or
withdrawn from such underwriting shall be excluded and withdrawn from the
registration.

               (c)  Expenses. The Holders shall be responsible for their pro
rata share of registration fees and underwriters' and brokers' discounts and
commissions relating to any Registrable Securities included in such
registration. Other registration expenses (such as legal and accounting fees of
counsel to the Company, printing fees, road show expenses, and the like) shall
be borne by the Company.

               (d)  Number of Piggyback Registrations. The piggyback
registration rights granted to the Holders under this Section shall apply to the
first three registrations filed by the Company after the Closing (excluding any
registrations filed under Section 7.2 of this Agreement.

               (e)  Suspension During Effectiveness of Shelf Registration. The
rights of the Holders and obligations of the Company under Sections 7.8(a)-(d)
shall be suspended during any period in which the Shelf Registration Statement
is effective.

     8.   ASSIGNMENT. Notwithstanding anything herein to the contrary, the
registration rights of a Holder under Section 7 hereof may be assigned only to a
party who acquires from such Holder at least 100,000 shares of Registrable
Securities (as such number may be adjusted to reflect subdivisions, combinations
and stock dividends of the Company's Common Stock), (such party is referred to
as an "Assignee"); provided, however, that (i) no party may be assigned any of
the foregoing rights until the Company is given written notice by the assigning
party at the time of such assignment stating the name and address of the
Assignee and identifying the securities of the Company as to which the rights in
question are being assigned; (ii) that any such Assignee shall receive such
assigned rights subject to all the terms and conditions of this Agreement; and
(iii) no such assignment or assignments shall increase the obligations of the
Company hereunder.

     9.   MISCELLANEOUS.

          9.1  Survival of Warranties. The representations, warranties and
covenants of the Company and the Investors contained in or made pursuant to this
Agreement shall survive the execution and delivery of this Agreement and the
Closing for a period of one year and shall in no way be affected by any
investigation of the subject matter thereof made by or on behalf of the
Investors, their counsel or the Company, as the case may be.

          9.2  Successors and Assigns. The terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties.

          9.3  Governing Law; Consent to Jurisdiction. This Agreement shall be
governed by and construed under the internal laws of the State of Delaware as
applied to agreements among Delaware residents entered into and to be performed
entirely within Delaware, without reference to principles of conflict of laws or
choice of laws.

<PAGE>

                                     - 14 -

          9.4  Counterparts. This Agreement may be executed in two or more
counterparts and by facsimile, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

          9.5  Headings. The headings and captions used in this Agreement are
used for convenience only and are not to be considered in construing or
interpreting this Agreement. All references in this Agreement to sections,
paragraphs, exhibits and schedules shall, unless otherwise provided, refer to
sections and paragraphs hereof and exhibits and schedules attached hereto, all
of which exhibits and schedules are incorporated herein by this reference.

          9.6  Notices. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified, by
telecopier or upon deposit with the United States Post Office, by registered or
certified mail, postage prepaid and addressed to the party to be notified in the
case of the Company, at Telular Corporation, 647 North Lakeview Parkway, Vernon
Hills, IL 60061, Attn: Jeffrey Herrmann, facsimile # 847-573-2011, with a copy
to Covington & Burling, 1201 Pennsylvania Ave., N.W., Washington, D.C. 20004,
Attn: Michael E. Cutler, facsimile # 202-662-6291, or in the case of the
Investor, at QUALCOMM Incorporated, 5775 Morehouse Dr., San Diego,CA 92121,
Attn: Jeff Altman, with a copy to the General Counsel at the same address,
facsimile # 858-845-1249, or at such other address as any party may designate by
giving ten (10) days advance written notice to the other party. Notices shall be
deemed delivered upon delivery if personally delivered, one business day after
transmission with confirmation of receipt if sent by telecopier, or three days
after deposit in the mails if mailed.

          9.7  No Finder's Fees. Each party represents that it neither is nor
will be obligated for any finder's or broker's fee or commission in connection
with this transaction. The Investor agrees to indemnify and to hold harmless the
Company from any liability for any commission or compensation in the nature of a
finder's or broker's fee (and any asserted liability) for which the Investor or
any of its officers, partners, employees, or representatives is responsible. The
Company agrees to indemnify and to hold harmless the Investor from any liability
for any commission or compensation in the nature of a finder's or broker's fee
(and any asserted liability) for which the Company or any of its officers,
employees or representatives is responsible.

          9.8  Costs, Expenses. Each party's costs in connection with the
preparation, execution delivery and performance of this Agreement (including
without limitation legal fees) shall be borne by that party.

          9.9  Amendments and Waivers. Any term of this Agreement may be amended
and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), only
with the written consent of the Company and the Investor. Subject to the
limitations set forth in the preceding sentence, any amendment or waiver
effected in accordance with this Section shall be binding upon each holder of
any Purchased Shares at the time outstanding, each future holder of such
securities, and the Company.

          9.10 Severability. If one or more provisions of this Agreement are
held to be invalid, illegal or unenforceable under applicable law, such
provision(s) shall be excluded from this Agreement and the balance of the
Agreement shall be interpreted as if such provision(s) were so excluded and
shall be enforceable in accordance with its terms.

<PAGE>

                                     - 15 -

          9.11 Entire Agreement. This Agreement, together with any exhibits or
schedules hereto, constitutes the entire agreement and understanding of the
parties with respect to the subject matter hereof and supersedes any and all
prior negotiations, correspondence, agreements, understandings duties or
obligations between the parties with respect to the subject matter hereof.

          9.12 Breach. A breach of any provision of this Agreement shall
constitute a breach of this Agreement and the Fixed Wireless CDMA Subscriber
Unit License Agreement dated April 14, 2003.

          9.13 Further Assurances. From and after the date of this Agreement,
upon the request of the Investor or the Company, the Company and the Investor
shall execute and deliver such instruments, documents or other writings as may
be reasonably necessary or desirable to confirm and carry out and to effectuate
fully the intent and purposes of this Agreement.

                [Remainder of this page intentionally left blank]

<PAGE>

                                     - 16 -

     IN WITNESS WHEREOF, the parties hereto have executed this Common Stock
Purchase Agreement as of the date first above written.

<TABLE>
<CAPTION>
THE COMPANY:                                   INVESTOR:
-----------                                    --------
<S>                                            <C>
Telular Corporation                            QUALCOMM Incorporated

By: /s/ Kenneth Millard                        By:  /s/ Marvin Blecker
    --------------------------------------          ---------------------------------
Name: Kenneth Millard                          Name: Marvin Blecker
     -------------------------------------          ---------------------------------
Title: President & Chief Executive Officer     Title: Senior Vice President & General
      ------------------------------------           --------------------------------
                                                      Manager Qualcomm Technology
                                                     --------------------------------
                                                      Licensing Division
                                                     --------------------------------
</TABLE>

                           COUNTERPART SIGNATURE PAGE
                        COMMON STOCK PURCHASE AGREEMENT]

<PAGE>

                                     - 17 -

                                    Exhibit A
                                    ---------
                               Opinion of Counsel

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]